Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.021
Handel nachbörslich:
.01
0.01
+
Schlusskurs vom Vortag:
$0.021
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.24M
KGV:
0.00
EPS:
-8.83
Netto-Cashflow:
$-16.85M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-99.74%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.2869
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Firmenname
Virpax Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie VRPX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.00 | 0 | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.92 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.24 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.26 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.29 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
Virpax Pharmaceuticals Inc Aktie (VRPX) Neueste Nachrichten
EBITDA per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
Virpax Pharmaceuticals Inc. (VRPX) Stock Price | Live Quotes & Charts | EXPM - StocksToTrade
Tangible book value per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
CapEx per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
RTW Biotech invests USD5.9 million in Yarrow Bioscience funding round - marketscreener.com
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
Stocks advance as Nvidia earnings light up global markets - marketscreener.com
Wall Street opens higher as Nvidia test looms - marketscreener.com
Analyzing Virpax Pharmaceuticals (NASDAQ:VRPX) and IMV (OTCMKTS:IMVIQ) - Defense World
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results - MSN
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Jones Expects Nasdaq to Climb Higher, Lower Rates - marketscreener.com
Virpax Pharmaceuticals, Inc.Common Stock (NQ: - FinancialContent
TNF Pharmaceuticals Regains Compliance With Nasdaq Listing Requirement - marketscreener.com
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Head-To-Head Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) vs. Evotec (OTCMKTS:EVTCY) - Defense World
Virpax reports positive study results for pain management drug - MSN
Top Nanotechnology Stocks To Follow Today – August 25th - Defense World
Hookipa Pharma to Voluntarily Delist From Nasdaq - marketscreener.com
Promising Nanotechnology Stocks To Watch Now – July 16th - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Down 2.9% – Should You Sell? - Defense World
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Top Nanotechnology Stocks To Follow NowJuly 10th - MarketBeat
Nanotechnology Stocks To Watch Today – July 7th - Defense World
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
VRPX Stock Price and Chart — OTC:VRPX - TradingView
VRPX stock plunges to 52-week low, touches $1.07 - Investing.com Australia
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes - TipRanks
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Reports on Progress of Envelta™ - Business Wire
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com
Virpax receives positive Probudur™ results for dose range study - TradingView
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - Stock Titan
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com South Africa
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Virpax Pharmaceuticals Announces Positive Results from U.S. Army Study on Probudur™ - Kalkine Media
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - FinancialContent
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals appoints new CFO By Investing.com - Investing.com Canada
Dow Theory LettersSpartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering - FinancialContent
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug - Stock Titan
VRPX stock touches 52-week low at $0.46 amid market challenges - Investing.com
Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy, Price Target is $173 - marketscreener.com
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com
Virpax Pharmaceuticals extends financing negotiation rights By Investing.com - Investing.com UK
Finanzdaten der Virpax Pharmaceuticals Inc-Aktie (VRPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
1.69%
Kapitalisierung:
|
Volumen (24h):